EFFECTIVE RESEARCH, INC.
HOLLYWOOD, FLORIDA

Effective Research, Inc., founded on March 20, 1998, is a Contract Research Organization (CRO) based in Hollywood, Florida. They are well-established and active in Broward County, with their mailing address at 832 S. Southlake Dr., Hollywood, FL, 33019. As a full-service CRO, they cater to pharmaceutical, biotechnology, and medical device companies by providing essential clinical development services across various therapeutic areas. The company prides itself on being highly responsive, maintaining integrity, and ensuring clear communication with clients throughout both planning and execution of trials. With over seven years of industry experience per staff member in a clinical operations setting, Effective Research demonstrates operational excellence and is recognized for offering tailored scientific, regulatory, and personnel expertise that meets very specific trial needs. Their philosophy centers around delivering high-quality services by understanding the pressures that project leaders face, and they strive to enhance product development via partnerships that prioritize quality outcomes delivered efficiently and cost-effectively without sacrificing precision. The company handles all aspects of clinical trial management, from starting to finishing the projects, while maintaining transparency in their financial dealings through straightforward contract pricing. This has helped them build a solid reputation for client retention due to high-quality performance grounded in experience and timely responsiveness. They also make communication easy, ensuring accessibility by providing current contact information: (954) 907-0417 and (954) 920-3122. Further details on their services can be found at effectiveresearch.com. Guided by leaders like Treasurer Ethan Singer and a principal decision-maker Scott Singer, Effective Research continues to grow within the industry. Marking significant milestones such as reinstatement on October 5, 2011, they adhere to consistent annual reporting, with their latest filing being on January 28, 2024, demonstrating their ongoing commitment to excellence in clinical research.